Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

September 30, 2006

Conditions
Pancreatic Cancer
Interventions
GENETIC

cetuximab

Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.

Trial Locations (10)

20052

Ospedale S.Gerardo, Via Donizetti, 106, Monza

20162

A.O. Cà Granda, Piazza Ospedale Maggiore, 3, Milan

24047

A.O. Treviglio-Caravaggio, P.le Ospedale n1, Treviglio

24128

Ospedali Riuniti, Largo Barozzi, 1, Bergamo

25100

Casa di Cura di Poliambulanza, Via Bissolati 57, Brescia

46100

A.O. Carlo Poma - Via Albertoni, 1, Mantova

50139

A.O. Careggi-Università, Viale Pieraccini, 17, Florence

57121

Azienda USL 6 - Viale Alfieri, 36, Livorno

60020

A.O. Ospedale Umberto I - Università - Località Torretta, Ancona

00155

Università Campus Biomedico, Via Emilio Longoni, 83, Roma

All Listed Sponsors
collaborator

Mario Negri Institute for Pharmacological Research

OTHER

lead

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

OTHER

NCT00536614 - Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer | Biotech Hunter | Biotech Hunter